Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals - Nature Metabolism

AI Analysis of Reddit Posts Identifies Potential Side Effects of GLP-1 Weight Loss Drugs

Researchers at the University of Pennsylvania used AI to analyze over 410,000 Reddit posts spanning six years to identify potential side eff

Study: GLP-1 Weight Loss Drugs Linked to Decline in Daily Physical Activity

A new study analyzing NIH All of Us Research Program data, including Fitbit activity records and electronic health records, reveals that adu

GLP-1 drugs show early promise for treating substance use disorders, but evidence remains preliminary

GLP-1 receptor agonists (like semaglutide and tirzepatide), already transformative for obesity and diabetes, are being investigated as a pot

Conflicts of interest threaten integrity of GLP-1 therapy guidance amid rapid adoption

This article discusses the rapid uptake and commercial success of GLP-1 receptor agonists for obesity management, highlighting their clinica

Triple hormone drug retatrutide shows promise for diabetes and weight loss in Lancet trial

A new triple hormone drug called retatrutide, which mimics GLP-1, GIP, and glucagon, has shown promising results in a Lancet-published trial